Page 263

Soignet, S.L., P. Maslak, Z.G. Wang, S. Jhanwar, E. Calleja, L.J. Dardashti, D. Corso, A. DeBlasio, J. Gabrilove, D.A. Scheinberg, P.P. Pandolfi, and R.P. Warrell, Jr.  1998.  Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 339:1341-1348.

Stockman, R. 1902. The therapeutic value of arsenic and the justification of its continued use in the light of recent observations concerning its toxic action. Br. Med. J. (Oct. 18):1227-1229.

Underwood, E.J. and W. Mertz. 1987. Introduction. Pp. 1-19 in Trace Elements in Human and Animal Nutrition, Vol. 1, 5th Ed., W. Mertz, ed. San Diego, Calif.: Academic.

Uthus, E.O. 1992. Evidence for arsenic essentiality. Environ. Geochem. Health 14:55-58.

Uthus, E.O., W.E. Cornatzer, and F.H. Nielsen. 1983. Consequences of arsenic deprivation in laboratory animals. Pp. 173-189 in Arsenic: Industrial, Biomedical, Environmental Perspectives, W.H. Lederer and R.J. Fensterheim, eds. New York: Van Nostrand Reinhold.

Vahter M., and H. Norin. 1980. Metabolism of 74 As-labeled trivalent and pentavalent inorganic arsenic in mice. Environ. Res. 21:446-457.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement